Cefazolin

證據等級: L5

預測適應症: 8 個

CEFAZOLIN: From Surgical Prophylaxis to Infectious Otitis Media

One-Sentence Summary

Cefazolin is a first-generation cephalosporin antibiotic, widely recognized as the gold-standard agent for perioperative surgical prophylaxis and treatment of gram-positive bacterial infections per ASHP and IDSA guidelines. The TxGNN model predicts it may be effective for Infectious Otitis Media (prediction score: 99.44%), with 1 clinical trial and 3 publications currently identified in support of this direction — though the clinical trial was terminated before completion and evidence remains at an observational level.

Quick Overview

Item	Content
Original Indication	Surgical prophylaxis; gram-positive bacterial infections (skin, soft tissue, urinary tract)
Predicted New Indication	Infectious Otitis Media
TxGNN Prediction Score	99.44%
Evidence Level	L3
Saudi Arabia Market Status	✗ Not Marketed
Number of Authorizations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Detailed mechanism of action data is not captured in this dataset. Based on established pharmacological knowledge, Cefazolin is a first-generation cephalosporin that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), disrupting peptidoglycan cross-linking and triggering bacterial lysis. Its antimicrobial spectrum is strongest against gram-positive organisms — particularly Staphylococcus aureus and Streptococcus pyogenes — with limited activity against gram-negative species.

The connection to infectious otitis media is mechanistically partial. Acute otitis media is most commonly caused by Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis, for which Cefazolin has significant coverage gaps. However, in cases where S. aureus or S. pyogenes are the predominant pathogens (a recognized minority of presentations), Cefazolin's spectrum aligns well. A 2025 case report (PMID 39567876) documents Cefazolin's use in Gradenigo syndrome — a rare, severe complication of petrous apicitis secondary to acute otitis media — as part of an empiric combination regimen targeting gram-positive organisms in a serious ENT infection.

The TxGNN model's high confidence score (99.44%) likely reflects the pathogen-level mechanistic overlap rather than a direct indication match. Clinically, Cefazolin's IV/IM-only route of administration and incomplete pathogen coverage reduce its practicality as a primary therapy for typical community-acquired otitis media, though there may be a niche role in inpatient or post-surgical ENT contexts.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT01511107	Phase 2	Terminated	520	Evaluated short-course (5-day) vs. standard-duration (10-day) antimicrobial therapy in children aged 6–23 months with acute otitis media; designed as a randomized, double-blind, placebo-controlled trial. Trial was terminated before completion. The specific antibiotic studied is not confirmed to be Cefazolin, and no efficacy results are available. The termination is an important caution signal.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
39567876	2025	Case Report	Ann Otol Rhinol Laryngol	Ceftazidime + Cefazolin empiric combination therapy for pediatric Gradenigo syndrome (a rare, severe complication of otitis media with petrous apicitis); supports Cefazolin's contribution as gram-positive coverage in complicated ENT infections where S. aureus and Streptococcus spp. are implicated
877649	1977	Review	Southern Med J	Overview of cephalosporin antibiotics in pediatric practice; notes the class's efficacy against gram-positive cocci and selected gram-negative bacilli, with potential application in pediatric ear infections, particularly in penicillin-allergic patients
3742953	1986	Case Series/Review	Clinical Pharmacy	Case review of Stevens-Johnson syndrome in a child who received Cefazolin during management of otitis media and febrile seizures; provides indirect evidence of historical Cefazolin use in the otitis media clinical context, and also raises awareness of hypersensitivity risk

Safety Considerations

Please refer to the package insert for safety information.

Note: One literature item (PMID 3742953) documents Stevens-Johnson syndrome in a patient receiving Cefazolin for an otitis media episode, and the mechanistic rationale for Rank 8 (allergic otitis media) explicitly flags that beta-lactam antibiotics — including Cefazolin — are known triggers for severe hypersensitivity reactions including anaphylaxis and SJS. This cross-sensitivity risk (approximately 1–2% with penicillin-allergic patients) warrants standard beta-lactam allergy screening before use.

Conclusion and Next Steps

Decision: Hold

Rationale: The sole identified clinical trial was terminated before completion and cannot confirm Cefazolin as the study agent, leaving the highest available evidence at the observational/case report level (L3). More fundamentally, Cefazolin's antimicrobial spectrum has insufficient coverage of the three most common pathogens in infectious otitis media (S. pneumoniae, H. influenzae, M. catarrhalis), making it unsuitable as a first-line empiric monotherapy for this indication without further subgroup stratification.

To proceed, the following is needed:

Pathogen subtype stratification: Identify patient populations with S. aureus- or S. pyogenes-predominant otitis media, where Cefazolin's spectrum is most relevant
Safety data gap (DG001): Retrieve full warnings and contraindications from the package insert before any clinical use assessment
MOA documentation (DG002): Formal DrugBank MOA data to complete the mechanistic linkage analysis
Route feasibility assessment: Clarify whether IV/IM administration is compatible with the target clinical setting (inpatient ENT vs. outpatient primary care)
Prospective study design: A protocol targeting Cefazolin as perioperative prophylaxis or adjunct treatment in complicated otitis media cases (e.g., Gradenigo syndrome, post-tympanoplasty) would be the most scientifically justified next step given current evidence
Saudi Arabia regulatory pathway: Since Cefazolin is not currently marketed in Saudi Arabia (0 authorizations), regulatory submission would require a full dossier prior to any market access strategy
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.